An insight into the use of estetrol-drospirenone as effective oral contraceptive

Abstract

Rise in population level is a major issue in today's world and according to United nations reports suggest the world population of 6 billion is expected to reach 9.7 billion by 2050. Contraception is an easy and direct method of reducing population growth. The popularity and success of contraception in the developed is testament to this. A total of 103 drugs were approved during the year 2020-2021 by the USFDA (United states food and drug administration) and the Estetrol-drospirenone (E4-DRSP) combination was one of them. E4-DRSP combination is the first oral contraceptive consisting of a natural estrogen Estetrol which is synthesized in the foetal liver. The other component is Drospirenone (DRSP) having anti-mineralocorticoid action and is a spironolactone derivative which makes the combination more effective. E4-DRSP is a combined oral contraceptive that is efficient, generally well-tolerated and may lower thrombosis risk. This review covers a detailed study of the E4-DRSP combination including its mechanism of action, pharmacology, adverse drug reactions, and clinical trials.

Keywords

• Estetrol
• Drospirenone
• Oral contraceptive
• And thrombosis